Amneal launches generic lidocaine ointment

BRIDGEWATER, N.J. — Amneal Pharmaceuticals this week launched a new lidocaine product line with the availability of its lidocaine 5% ointment. The company said that it hopes to expand the line with a transdermal patch formulation, which is currently waiting for final approval from the Food and Drug Administration. 

 

“Lidocaine ointment is our third topical medication and, once approved, the patch will be our first transdermal product,” Amneal’s EVP sales and marketing Jim Luce said.  “These two additions to our portfolio demonstrate our commitment to expand into new, more complex dosage forms valued by our pharmacy customers and their patients.”

 

The annual sales for lidocaine ointment in the United States were $251 million for the year ending September 2015, according to IMS Health data. The cream will be available in a 50-g jar and a 35.44-g tube with a child-resistant cap.